More Videos
SPECIAL REPORT
MOST SHARED
- Chinese Overcapacity is Worsening, EU Chamber Warns
- Gold Retreats from New High Above $1,194
- US Mint to Suspend American Eagle Gold 1-Ounce Coins
- The Executive Job Search
- China Unveils Carbon Target Ahead of Copenhagen
- Hyundai-Kia Targets Rapid China Growth in 2010
- Black Friday: Bargain or Bust?
- Wal-Mart Price Pressure Hurts China Workers: Report
- Trader Talk
- 4 Thanksgiving Week Buys For Your Portfolio: Market Pros
- There's a 'Great Chance' For a Double-Dip Recession: Strategist
- Revenge of the Gangsta Nerds
- Will TCU See The "Flutie Effect?"
- Retail Earnings and Sales to Improve in Q4: Analyst
- Consumers Catching the Holiday Spirit
- It's Beginning To Look A Lot More Riskless
- Crescenzi: Claims Level Suggests End to Job Losses
- Hedge Funds Take Early Lead in Warren Buffett's 'Big Bet'
- US Companies Already Moving on Cutting Emissions
- Fannie Mae to Tighten Lending Standards: Report
- Share Trading on London Stock Exchange Resumes
- China Overcapacity Worsening, EU Chamber Warns
- Investing in Good Karma – and Making a Profit
- UK Retail Sales Pick Up in Nov., Strong Dec. Seen
- Black Friday to Avoid Red Ink; Greenback Gets the Blues
- Wal-Mart Price Pressure Hurts China Workers: Report
- Bankruptcies Jump, Hitting Highest Level in Four Years
PHARMA'S MARKET VIDEO
RSS FEED
Pharma's Market
Text Size 
As promised, I will reveal the top-performing Nasdaq 100 stock of 2008--barring some 11th-hour stock-moving event in the last few days of the year.
The Nasdaq is down 42 percent this year. Its worst year ever. The Nasdaq biotech index has held up significantly better, but it still fell 16 percent.
And then there's Vertex Pharmaceuticals [VRTX
Loading...
()
]. As of Friday's close it was up 27 percent in 2008. The stock's been on a roller-coaster as investor sentiment swings back and forth over the perceived prospects for VRTX's drug for hepatitis C. So, I was surprised when I read our stock statistician's email last Friday evening pointing out that VRTX's 27 percent rise makes it the best performing stock in the Nasdaq 100 this year.
Vertex is in a race with Schering-Plough [SGP
Loading...
()
] to bring a good new drug for hep C to market. Investors could get another update on Vertex's progress when it presents at the JPMorgan Healthcare Conference in a few weeks.
As always, we'll be at the San Francisco event with a full lineup of live interviews with C-suite execs, including Vertex's Joshua Boger. I guess he'll get to take a victory lap for VRTX's whopping 70 percent outperformance of the Nasdaq this year.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes